PL372138A1 - Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) - Google Patents

Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)

Info

Publication number
PL372138A1
PL372138A1 PL02372138A PL37213802A PL372138A1 PL 372138 A1 PL372138 A1 PL 372138A1 PL 02372138 A PL02372138 A PL 02372138A PL 37213802 A PL37213802 A PL 37213802A PL 372138 A1 PL372138 A1 PL 372138A1
Authority
PL
Poland
Prior art keywords
tfpi
sepsis
treatment
low dose
tissue factor
Prior art date
Application number
PL02372138A
Other languages
English (en)
Polish (pl)
Inventor
Abla A. Creasey
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of PL372138A1 publication Critical patent/PL372138A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL02372138A 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) PL372138A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15

Publications (1)

Publication Number Publication Date
PL372138A1 true PL372138A1 (en) 2005-07-11

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
PL02372138A PL372138A1 (en) 2001-10-15 2002-10-15 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
PL02374506A PL374506A1 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL02374506A PL374506A1 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Country Status (17)

Country Link
US (2) US7674769B2 (enExample)
EP (2) EP1446140A4 (enExample)
JP (5) JP2005506345A (enExample)
KR (2) KR20040040489A (enExample)
CN (2) CN1604790A (enExample)
AU (2) AU2002365131B2 (enExample)
BR (2) BR0213293A (enExample)
CA (2) CA2463655A1 (enExample)
EA (2) EA200400549A1 (enExample)
HU (2) HUP0501111A2 (enExample)
IL (2) IL161407A0 (enExample)
IS (2) IS7224A (enExample)
MX (2) MXPA04003547A (enExample)
NO (2) NO20041997D0 (enExample)
PL (2) PL372138A1 (enExample)
WO (2) WO2003032904A2 (enExample)
ZA (2) ZA200403601B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400549A1 (ru) * 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
JP4522997B2 (ja) * 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
JP2008536859A (ja) * 2005-04-15 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 組織因子経路阻害剤（ｔｆｐｉ）の投与による重度の市中肺炎の処置
KR20080017021A (ko) * 2005-05-06 2008-02-25 노바티스 아게 중증 박테리아 감염을 치료하기 위한 ｔｆｐｉ의 용도
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
CN101262880A (zh) * 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
CA2615777A1 (en) * 2005-07-22 2007-02-01 Novartis Ag Tfpi fragments as anti-microbial agents
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
WO2013011021A1 (en) 2011-07-18 2013-01-24 The University Of Melbourne Use of c-fms antagonists
KR101672108B1 (ko) 2011-11-15 2016-11-02 아사히 가세이 파마 가부시키가이샤 패혈증의 치료 및/또는 개선을 위한 의약
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
WO1985004899A1 (en) 1984-04-19 1985-11-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
DK0473564T3 (da) 1990-08-27 1996-04-15 Monsanto Co Antikoagulant kombination af LACI og sulfatiserede polysaccharider
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
DE69327314T2 (de) * 1992-06-01 2000-04-13 Chiron Corp., Emeryville Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
KR950701820A (ko) 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
JPH11514334A (ja) 1995-06-07 1999-12-07 チロン コーポレーション タンパク質の可溶化、精製、および再生の方法
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
KR100442758B1 (ko) 1996-03-25 2004-10-06 사이단호진 가가쿠오요비겟세이료호겐쿠쇼 조직인자응고계억제제함유혈관신생저해제
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US6262233B1 (en) * 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
EP1124573A1 (en) 1998-10-22 2001-08-22 Eli Lilly And Company Methods for treating sepsis
EP1131091B1 (en) 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
AU4683299A (en) * 1999-06-11 2001-01-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
WO2000077246A2 (en) 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
AU2908501A (en) 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
JP2003523348A (ja) 2000-02-16 2003-08-05 ノースウェスタン ユニバーシティ ポリペプトイド肺サーファクタント
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
WO2002099098A1 (en) 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EA200400549A1 (ru) 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
NO20041997D0 (no) 2004-05-14
ZA200403601B (en) 2006-06-28
EP1446138A2 (en) 2004-08-18
BR0213293A (pt) 2004-12-21
HUP0501111A2 (en) 2007-12-28
CN1604787A (zh) 2005-04-06
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (en) 2007-03-07
EP1446138A4 (en) 2007-03-14
IS7223A (is) 2004-04-15
US20030139339A1 (en) 2003-07-24
JP2005515214A (ja) 2005-05-26
US20030139340A1 (en) 2003-07-24
AU2002365131A1 (en) 2003-07-15
JP2010006839A (ja) 2010-01-14
MXPA04003547A (es) 2004-07-22
IS7224A (is) 2004-04-15
CA2463655A1 (en) 2003-04-24
EP1446140A2 (en) 2004-08-18
WO2003055442A3 (en) 2004-03-04
JP2006008706A (ja) 2006-01-12
JP2005506345A (ja) 2005-03-03
HUP0500472A2 (hu) 2005-08-29
NO20041996D0 (no) 2004-05-14
JP2006008704A (ja) 2006-01-12
WO2003032904A2 (en) 2003-04-24
EA200400549A1 (ru) 2005-02-24
CA2463738A1 (en) 2003-07-10
AU2002365131B2 (en) 2007-03-01
IL161408A0 (en) 2004-09-27
US7674769B2 (en) 2010-03-09
BR0213292A (pt) 2006-05-23
KR20050036867A (ko) 2005-04-20
IL161407A0 (en) 2004-09-27
MXPA04003548A (es) 2004-07-22
CN1604790A (zh) 2005-04-06
ZA200403690B (en) 2005-03-08
KR20040040489A (ko) 2004-05-12
WO2003055442A2 (en) 2003-07-10
WO2003032904A3 (en) 2004-03-04
PL374506A1 (en) 2005-10-31
AU2002340183B2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
IL161408A0 (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
AU5977401A (en) Delivery devices for treatment of vascular disease
GB0126151D0 (en) Administration of medicaments by vaporisation
IL163725A0 (en) Administration of agents for the treatment of inflammation
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
AU2003297621A8 (en) Medical devices for delivery of therapeutic agents
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL370818A1 (en) Dosage form for treatment of diabetes mellitus
EP1416884A4 (en) DISTRIBUTION OF AGENTS WITH THERAPEUTIC PROPERTIES
AU2002310325A1 (en) Use of ozone for the prevention of infection caused by medical devices
HUP0401501A3 (en) Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
ZA200410229B (en) Administration of therapeutic viruses
EP1461024A4 (en) TREATMENT OF WOUNDS AND COMPOSITIONS USED
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
GB0130677D0 (en) Medicaments and novel compounds
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
HUP0303029A3 (en) Use of pharmaceutical compositions containing cgmp-5pde inhibitors for treatment of wounds
IL155819A0 (en) Methods of treatment comprising administration of substance p
IL158900A0 (en) Pharmaceutical compositions containing a tricyclic compound for the prevention or treatment of skin diseases
IL178115A0 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1451308A4 (en) THERAPEUTIC USE OF AZIRIDINO COMPOUNDS
DE60230609D1 (de) Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen durch inhalation
GB0119115D0 (en) Formulation for treatment of gallstones

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)